Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective

Download Type: Adobe PDF

The pharmaceutical industry is under huge pressure to overhaul what is currently viewed as a highly inefficient operating model. Unacceptable levels of late-stage failure in clinical development remain a fundamental problem for the sector. Lack of efficacy is a major reason for candidate failure and a lack of understanding of disease biology is considered to be a key issue underpinning this problem. There has been a recent upsurge in interest from pharmaceutical and biotechnology companies to collaborate with academic institutions, with the latter viewed as being home to research teams with in-depth biological knowledge and translational research expertise.

In this article Robert J. Williams, Ian Walker and Andrew K. Takle outline models for collaboration in drug discovery and development being pursued by the research-based charity Cancer Research UK (CR-UK).

Share this download

More services